Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City
DURHAM, NC / ACCESSWIRE / August 29, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced it will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at The St. Regis New York in New York City.
Jeff Wolf, Founder and Chief Executive Officer of Heat Biologics, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: 20th Annual Rodman & Renshaw Global Investment Conference
Date: Wednesday, September 5, 2018
Time: 4:40-5:05 PM (Eastern Time)
Location: Louis XVI B; The St. Regis New York
If you are unable to attend and would like to view the Company's live webcast, please click on the following link (http://wsw.com/webcast/rrshq28/htbx/).
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.
Media and Investor Relations Contact
+1 919 289 4017
SOURCE: Heat Biologics, Inc.
Released August 29, 2018